195 related articles for article (PubMed ID: 17335304)
1. Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer.
Simoens S
Pharmacoeconomics; 2007; 25(3):181-5. PubMed ID: 17335304
[No Abstract] [Full Text] [Related]
2. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab for early breast cancer: evolution or revolution?
Littlejohns P
Lancet Oncol; 2006 Jan; 7(1):22-3. PubMed ID: 16408378
[No Abstract] [Full Text] [Related]
4. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
Reed SD; Schulman KA
Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
6. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
Garrison LP; Veenstra DL
Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
[TBL] [Abstract][Full Text] [Related]
7. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.
Phillips KA; Marshall DA; Haas JS; Elkin EB; Liang SY; Hassett MJ; Ferrusi I; Brock JE; Van Bebber SL
Cancer; 2009 Nov; 115(22):5166-74. PubMed ID: 19753618
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab in breast cancer.
Mastrianni DM
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
[No Abstract] [Full Text] [Related]
9. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.
Van Vlaenderen I; Canon JL; Cocquyt V; Jerusalem G; Machiels JP; Neven P; Nechelput M; Delabaye I; Gyldmark M; Annemans L
Acta Clin Belg; 2009; 64(2):100-12. PubMed ID: 19432022
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
[TBL] [Abstract][Full Text] [Related]
12. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
Chen W; Jiang Z; Shao Z; Sun Q; Shen K
Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
14. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
[TBL] [Abstract][Full Text] [Related]
15. How much will Herceptin really cost?
Barrett A; Roques T; Small M; Smith RD
BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.
Norum J
Expert Opin Pharmacother; 2006 Aug; 7(12):1617-25. PubMed ID: 16872264
[TBL] [Abstract][Full Text] [Related]
17. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
Roukos DH
J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
[No Abstract] [Full Text] [Related]
18. Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.
Younis T; Skedgel C
Pharmacoeconomics; 2011 May; 29(5):361-5. PubMed ID: 21504237
[No Abstract] [Full Text] [Related]
19. Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).
Bonneterre ME; Bonneterre J
Ann Oncol; 2006 May; 17(5):875; reply 875-6. PubMed ID: 16303862
[No Abstract] [Full Text] [Related]
20. Patient demand and politics push Herceptin forward.
Kondro W; Sibbald B
CMAJ; 2005 Aug; 173(4):347-8. PubMed ID: 16103498
[No Abstract] [Full Text] [Related]
[Next] [New Search]
